Monitoring T cell alloreactivity

Transplantation Reviews

Volumn 29, Issue 2, 2015, Pages 53-59

  Mehrotra, Anita ^a   Leventhal, Jeremy ^a   Purroy, Carolina ^a   Cravedi, Paolo ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; BIOLOGICAL MARKER; ALLOANTIBODY; CYTOKINE; IMMUNOSUPPRESSIVE AGENT;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; CHRONIC GRAFT REJECTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; GRAFT RECIPIENT; HUMAN; IMMUNE CELL FUNCTION ASSAY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; MIXED LYMPHOCYTE REACTION; OUTCOME ASSESSMENT; PATIENT MONITORING; PERSONALIZED MEDICINE; PHENOTYPE; POSTOPERATIVE PERIOD; REGULATORY T LYMPHOCYTE; RELIABILITY; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; GRAFT REJECTION; IMMUNOLOGICAL MONITORING; LYMPHOCYTE ACTIVATION; METABOLISM; MIXED LYMPHOCYTE CULTURE; PHYSIOLOGY;

BIOMARKERS; CYTOKINES; ENZYME-LINKED IMMUNOSPOT ASSAY; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MONITORING, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 84928142787     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2014.11.001     Document Type: Review

References (101)

1. Tantravahi J., Womer K.L., Kaplan B. Why hasn't eliminating acute rejection improved graft survival?. Annu Rev Med 2007, 58:369-385.
2. Schwarz A., Gwinner W., Hiss M., Radermacher J., Mengel M., Haller H. Safety and adequacy of renal transplant protocol biopsies. Am J Transplant 2005, 5:1992-1996.
3. Mannon R.B., Kirk A.D. Beyond histology: novel tools to diagnose allograft dysfunction. Clin J Am Soc Nephrol 2006, 1:358-366.
4. Rush D. Protocol transplant biopsies: an underutilized tool in kidney transplantation. Clin J Am Soc Nephrol 2006, 1:138-143.
5. Gloor J.M., Cohen A.J., Lager D.J., et al. Subclinical rejection in tacrolimus-treated renal transplant recipients. Transplantation 2002, 73:1965-1968.
6. Nankivell B.J., Borrows R.J., Fung C.L., O'Connell P.J., Allen R.D., Chapman J.R. Natural history, risk factors, and impact of subclinical rejection in kidney transplantation. Transplantation 2004, 78:242-249.
7. Rush D., Winnipeg Transplant G Insights into subclinical rejection. Transplant Proc 2004, 36:71S-73S.
8. Biomarkers Definitions Working G Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
9. Cravedi P., Heeger P.S. Immunologic monitoring in transplantation revisited. Curr Opin Organ Transplant 2012, 17:26-32.
10. Lodhi S.A., Lamb K.E., Meier-Kriesche H.U. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011, 11:1226-1235.
11. Lechler R.I., Lombardi G., Batchelor J.R., Reinsmoen N., Bach F.H. The molecular basis of alloreactivity. Immunol Today 1990, 11:83-88.
12. Shoskes D.A., Wood K.J. Indirect presentation of MHC antigens in transplantation. Immunol Today 1994, 15:32-38.
13. Lechler R.I., Batchelor J.R. Immunogenicity of retransplanted rat kidney allografts. Effect of inducing chimerism in the first recipient and quantitative studies on immunosuppression of the second recipient. J Exp Med 1982, 156:1835-1841.
14. Lechler R.I., Batchelor J.R. Restoration of immunogenicity to passenger cell-depleted kidney allografts by the addition of donor strain dendritic cells. J Exp Med 1982, 155:31-41.
15. van Besouw N.M., Zuijderwijk J.M., Vaessen L.M., et al. The direct and indirect allogeneic presentation pathway during acute rejection after human cardiac transplantation. Clin Exp Immunol 2005, 141:534-540.
16. Baker R.J., Hernandez-Fuentes M.P., Brookes P.A., Chaudhry A.N., Cook H.T., Lechler R.I. Loss of direct and maintenance of indirect alloresponses in renal allograft recipients: implications for the pathogenesis of chronic allograft nephropathy. J Immunol 2001, 167:7199-7206.
17. Vella J.P., Spadafora-Ferreira M., Murphy B., et al. Indirect allorecognition of major histocompatibility complex allopeptides in human renal transplant recipients with chronic graft dysfunction. Transplantation 1997, 64:795-800.
18. Sayegh M.H., Carpenter C.B. Role of indirect allorecognition in allograft rejection. Int Rev Immunol 1996, 13:221-229.
19. Bestard O., Nickel P., Cruzado J.M., et al. Circulating alloreactive T cells correlate with graft function in longstanding renal transplant recipients. J Am Soc Nephrol 2008, 19:1419-1429.
20. Thomas F.T., Lee H.M., Lower R.R., Thomas J.M. Immunological monitoring as a guide to the management of transplant recipients. Surg Clin North Am 1979, 59:253-281.
21. Ghobrial I.I., Morris A.G., Booth L.J. Clinical significance of in vitro donor-specific hyporesponsiveness in renal allograft recipients as demonstrated by the MLR. Transpl Int 1994, 7:420-427.
22. Hernandez-Fuentes M.P., Warrens A.N., Lechler R.I. Immunologic monitoring. Immunol Rev 2003, 196:247-264.
23. Tanaka Y., Tashiro H., Onoe T., Ide K., Ishiyama K., Ohdan H. Optimization of immunosuppressive therapy based on a multiparametric mixed lymphocyte reaction assay reduces infectious complications and mortality in living donor liver transplant recipients. Transplant Proc 2012, 44:555-559.
24. Ashokkumar C., Talukdar A., Sun Q., et al. Allospecific CD154+ T cells associate with rejection risk after pediatric liver transplantation. Am J Transplant 2009, 9:179-191.
25. Page A.J., Ford M.L., Kirk A.D. Memory T-cell-specific therapeutics in organ transplantation. Curr Opin Organ Transplant 2009, 14:643-649.
26. Woodland D.L., Kohlmeier J.E. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol 2009, 9:153-161.
27. Pearl J.P., Parris J., Hale D.A., et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005, 5:465-474.
28. Dinavahi R., Heeger P.S. T-cell immune monitoring in organ transplantation. Curr Opin Organ Transplant 2008, 13:419-424.
29. Mashishi T., Gray C.M. The ELISPOT assay: an easily transferable method for measuring cellular responses and identifying T cell epitopes. Clin Chem Lab Med 2002, 40:903-910.
30. Heeger P.S., Greenspan N.S., Kuhlenschmidt S., et al. Pretransplant frequency of donor-specific, IFN-gamma-producing lymphocytes is a manifestation of immunologic memory and correlates with the risk of posttransplant rejection episodes. J Immunol 1999, 163:2267-2275.
31. Augustine J.J., Siu D.S., Clemente M.J., Schulak J.A., Heeger P.S., Hricik D.E. Pre-transplant IFN-gamma ELISPOTs are associated with post-transplant renal function in African American renal transplant recipients. Am J Transplant 2005, 5:1971-1975.
32. Augustine J.J., Poggio E.D., Clemente M., et al. Hemodialysis vintage, black ethnicity, and pretransplantation antidonor cellular immunity in kidney transplant recipients. J Am Soc Nephrol 2007, 18:1602-1606.
33. Nickel P., Presber F., Bold G., et al. Enzyme-linked immunosorbent spot assay for donor-reactive interferon-gamma-producing cells identifies T-cell presensitization and correlates with graft function at 6 and 12months in renal-transplant recipients. Transplantation 2004, 78:1640-1646.
34. Kim S.H., Oh E.J., Kim M.J., et al. Pretransplant donor-specific interferon-gamma ELISPOT assay predicts acute rejection episodes in renal transplant recipients. Transplant Proc 2007, 39:3057-3060.
35. Koscielska-Kasprzak K., Drulis-Fajdasz D., Kaminska D., et al. Pretransplantation cellular alloreactivity is predictive of acute graft rejection and 1-year graft function in kidney transplant recipients. Transplant Proc 2009, 41:3006-3008.
36. Hricik D.E., Rodriguez V., Riley J., et al. Enzyme linked immunosorbent spot (ELISPOT) assay for interferon-gamma independently predicts renal function in kidney transplant recipients. Am J Transplant 2003, 3:878-884.
37. Nather B.J., Nickel P., Bold G., et al. Modified ELISPOT technique - highly significant inverse correlation of post-Tx donor-reactive IFNgamma-producing cell frequencies with 6 and 12months graft function in kidney transplant recipients. Transpl Immunol 2006, 16:232-237.
38. Bestard O., Cruzado J.M., Lucia M., et al. Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney Int 2013, 84:1226-1236.
39. Augustine J.J., Poggio E.D., Heeger P.S., Hricik D.E. Preferential benefit of antibody induction therapy in kidney recipients with high pretransplant frequencies of donor-reactive interferon-gamma enzyme-linked immunosorbent spots. Transplantation 2008, 86:529-534.
40. Cherkassky L., Lanning M., Lalli P.N., et al. Evaluation of alloreactivity in kidney transplant recipients treated with antithymocyte globulin versus IL-2 receptor blocker. Am J Transplant 2011, 11:1388-1396.
41. Andree H., Nickel P., Nasiadko C., et al. Identification of dialysis patients with panel-reactive memory T cells before kidney transplantation using an allogeneic cell bank. J Am Soc Nephrol 2006, 17:573-580.
42. Poggio E.D., Augustine J.J., Clemente M., et al. Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection. Transplantation 2007, 83:847-852.
43. Pawlik A., Florczak M., Masiuk M., et al. The expansion of CD4+ CD28- T cells in patients with chronic kidney graft rejection. Transplant Proc 2003, 35:2902-2904.
44. Azuma M., Phillips J.H., Lanier L.L. CD28- T lymphocytes. Antigenic and functional properties. J Immunol 1993, 150:1147-1159.
45. Brzezinska A., Magalska A., Szybinska A., Sikora E. Proliferation and apoptosis of human CD8(+)CD28(+) and CD8(+)CD28(-) lymphocytes during aging. Exp Gerontol 2004, 39:539-544.
46. Scheuring U.J., Sabzevari H., Theofilopoulos A.N. Proliferative arrest and cell cycle regulation in CD8(+)CD28(-) versus CD8(+)CD28(+) T cells. Hum Immunol 2002, 63:1000-1009.
47. Tortorella C., Pisconti A., Piazzolla G., Antonaci S. APC-dependent impairment of T cell proliferation in aging: role of CD28- and IL-12/IL-15-mediated signaling. Mech Ageing Dev 2002, 123:1389-1402.
48. Traitanon O., Gorbachev A., Bechtel J.J., et al. IL-15 induces alloreactive CD28(-) memory CD8 T cell proliferation and CTLA4-Ig resistant memory CD8 T cell activation. Am J Transplant 2014, 14:1277-1289.
49. Taylor A.L., Negus S.L., Negus M., Bolton E.M., Bradley J.A., Pettigrew G.J. Pathways of helper CD4 T cell allorecognition in generating alloantibody and CD8 T cell alloimmunity. Transplantation 2007, 83:931-937.
50. Conlon T.M., Saeb-Parsy K., Cole J.L., et al. Germinal center alloantibody responses are mediated exclusively by indirect-pathway CD4 T follicular helper cells. J Immunol 2012, 188:2643-2652.
51. Steele D.J., Laufer T.M., Smiley S.T., et al. Two levels of help for B cell alloantibody production. J Exp Med 1996, 183:699-703.
52. Poggio E.D., Clemente M., Riley J., et al. Alloreactivity in renal transplant recipients with and without chronic allograft nephropathy. J Am Soc Nephrol 2004, 15:1952-1960.
53. Illigens B.M., Yamada A., Anosova N., Dong V.M., Sayegh M.H., Benichou G. Dual effects of the alloresponse by Th1 and Th2 cells on acute and chronic rejection of allotransplants. Eur J Immunol 2009, 39:3000-3009.
54. Reznik S.I., Jaramillo A., SivaSai K.S., et al. Indirect allorecognition of mismatched donor HLA class II peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Am J Transplant 2001, 1:228-235.
55. Stegmann S., Muller A., Zavazava N. Synthetic HLA-A2 derived peptides are recognized and presented in renal graft recipients. Hum Immunol 2000, 61:1363-1369.
56. Benichou G., Valujskikh A., Heeger P.S. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999, 162:352-358.
57. Ciubotariu R., Liu Z., Colovai A.I., et al. Persistent allopeptide reactivity and epitope spreading in chronic rejection of organ allografts. J Clin Invest 1998, 101:398-405.
58. Womer K.L., Stone J.R., Murphy B., Chandraker A., Sayegh M.H. Indirect allorecognition of donor class I and II major histocompatibility complex peptides promotes the development of transplant vasculopathy. J Am Soc Nephrol 2001, 12:2500-2506.
59. Smith H.J., Hanvesakul R., Bentall A., et al. T Lymphocyte responses to nonpolymorphic HLA-derived peptides are associated with chronic renal allograft dysfunction. Transplantation 2011, 91:279-286.
60. Boisgerault F., Anosova N.G., Tam R.C., Illigens B.M., Fedoseyeva E.V., Benichou G. Induction of T-cell response to cryptic MHC determinants during allograft rejection. Hum Immunol 2000, 61:1352-1362.
61. Lovegrove E., Pettigrew G.J., Bolton E.M., Bradley J.A. Epitope mapping of the indirect T cell response to allogeneic class I MHC: sequences shared by donor and recipient MHC may prime T cells that provide help for alloantibody production. J Immunol 2001, 167:4338-4344.
62. Ashoor I., Najafian N., Korin Y., et al. Standardization and cross validation of alloreactive IFNgamma ELISPOT assays within the clinical trials in organ transplantation consortium. Am J Transplant 2013, 13:1871-1879.
63. Bestard O., Crespo E., Stein M., et al. Cross-validation of IFN-gamma Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients. Am J Transplant 2013, 13:1880-1890.
64. Josefowicz S.Z., Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009, 30:616-625.
65. Maynard C.L., Harrington L.E., Janowski K.M., et al. Regulatory T cells expressing interleukin 10 develop from Foxp3+ and Foxp3- precursor cells in the absence of interleukin 10. Nat Immunol 2007, 8:931-941.
66. Collison L.W., Workman C.J., Kuo T.T., et al. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007, 450:566-569.
67. Joffre O., Santolaria T., Calise D., et al. Prevention of acute and chronic allograft rejection with CD4+ CD25+ Foxp3+ regulatory T lymphocytes. Nat Med 2008, 14:88-92.
68. Wang J., Ioan-Facsinay A., van der Voort E.I., Huizinga T.W., Toes R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol 2007, 37:129-138.
69. Louis S., Braudeau C., Giral M., et al. Contrasting CD25hiCD4+ T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation 2006, 81:398-407.
70. He Q., Fan H., Li J.Q., Qi H.Z. Decreased circulating CD4+ CD25highFoxp3+ T cells during acute rejection in liver transplant patients. Transplant Proc 2011, 43:1696-1700.
71. Perrella O., Sbreglia C., Arenga G., et al. Acute rejection after liver transplantation: is there a specific immunological pattern?. Transplant Proc 2006, 38:3594-3596.
72. Demirkiran A., Kok A., Kwekkeboom J., et al. Low circulating regulatory T-cell levels after acute rejection in liver transplantation. Liver Transpl 2006, 12:277-284.
73. Ashton-Chess J., Dugast E., Colvin R.B., et al. Regulatory, effector, and cytotoxic T cell profiles in long-term kidney transplant patients. J Am Soc Nephrol 2009, 20:1113-1122.
74. Dijke I.E., Korevaar S.S., Caliskan K., et al. Inadequate immune regulatory function of CD4+ CD25bright+ FoxP3+ T cells in heart transplant patients who experience acute cellular rejection. Transplantation 2009, 87:1191-1200.
75. Akl A., Jones N.D., Rogers N., et al. An investigation to assess the potential of CD25highCD4+ T cells to regulate responses to donor alloantigens in clinically stable renal transplant recipients. Transpl Int 2008, 21:65-73.
76. Koshiba T., Li Y., Takemura M., et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007, 17:94-97.
77. Martinez-Llordella M., Puig-Pey I., Orlando G., et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007, 7:309-319.
78. Martinez-Llordella M., Lozano J.J., Puig-Pey I., et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008, 118:2845-2857.
79. Chen X., Oppenheim J.J. Resolving the identity myth: key markers of functional CD4+ FoxP3+ regulatory T cells. Int Immunopharmacol 2011, 11:1489-1496.
80. Braudeau C., Racape M., Giral M., et al. Variation in numbers of CD4+ CD25highFOXP3+ T cells with normal immuno-regulatory properties in long-term graft outcome. Transpl Int 2007, 20:845-855.
81. Kreijveld E., Koenen H.J., van Cranenbroek B., van Rijssen E., Joosten I., Hilbrands L.B. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS One 2008, 3:e2711. 10.1371/journal.pone.0002711.
82. Akimova T., Kamath B.M., Goebel J.W., et al. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am J Transplant 2012, 12:3449-3461.
83. Canavan J.B., Afzali B., Scotta C., et al. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 2012, 119:e57-e66.
84. Vallotton L., Hadaya K., Venetz J.P., et al. Monitoring of CD4+ CD25highIL-7Ralpha high activated T cells in kidney transplant recipients. Clin J Am Soc Nephrol 2011, 6:2025-2033.
85. Hope C.M., Grace B.S., Pilkington K.R., Coates P.T., Bergmann I.P., Carroll R.P. The immune phenotype may relate to cancer development in kidney transplant recipients. Kidney Int 2014, 86:175-183.
86. Ruggenenti P., Perico N., Gotti E., et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007, 84:956-964.
87. Mathew T., Kreis H., Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004, 18:446-449.
88. Kowalski R., Post D., Schneider M.C., et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003, 17:77-88.
89. Kowalski R.J., Post D.R., Mannon R.B., et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006, 82:663-668.
90. Bhorade S.M., Janata K., Vigneswaran W.T., Alex C.G., Garrity E.R. Cylex ImmuKnow assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008, 27:990-994.
91. Kobashigawa J.A., Kiyosaki K.K., Patel J.K., et al. Benefit of immune monitoring in heart transplant patients using ATP production in activated lymphocytes. J Heart Lung Transplant 2010, 29:504-508.
92. Millan O., Sanchez-Fueyo A., Rimola A., et al. Is the intracellular ATP concentration of CD4+ T-cells a predictive biomarker of immune status in stable transplant recipients?. Transplantation 2009, 88:S78-S84.
93. Sanchez-Velasco P., Rodrigo E., Valero R., et al. Intracellular ATP concentrations of CD4 cells in kidney transplant patients with and without infection. Clin Transplant 2008, 22:55-60.
94. Perez-Flores I., Sanchez-Fructuoso A., Santiago J.L., et al. Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients. Transplant Proc 2009, 41:2106-2108.
95. Nobuoka Y., Mizuno S., Nishikawa K., et al. Immune response following liver transplantation compared to kidney transplantation: usefulness of monitoring peripheral blood CD4+ adenosine triphosphate activity and cytochrome P450 3A5 genotype assay. Clin Dev Immunol 2013, 2013:936063. 10.1155/2013/936063.
96. Huskey J., Gralla J., Wiseman A.C. Single time point immune function assay (ImmuKnow) testing does not aid in the prediction of future opportunistic infections or acute rejection. Clin J Am Soc Nephrol 2011, 6:423-429.
97. Ryan C.M., Chaudhuri A., Concepcion W., Grimm P.C. Immune cell function assay does not identify biopsy-proven pediatric renal allograft rejection or infection. Pediatr Transplant 2014, 18:446-452.
98. Ling X., Xiong J., Liang W., et al. Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis. Transplantation 2012, 93:737-743.
99. Libri I., Gnappi E., Zanelli P., et al. Trends in immune cell function assay and donor-specific HLA antibodies in kidney transplantation: a 3-year prospective study. Am J Transplant 2013, 13:3215-3222.
100. Myslik F., House A.A., Yanko D., et al. Preoperative Cylex assay predicts rejection risk in patients with kidney transplant. Clin Transplant 2014, 28:606-610.
101. Brodin P., Valentini D., Uhlin M., Mattsson J., Zumla A., Maeurer M.J. Systems level immune response analysis and personalized medicine. Expert Rev Clin Immunol 2013, 9:307-317.